Aspergillosis
Aspergillosis is a group of illnesses caused by the mold Aspergillus. Most people inhale its spores without becoming ill, but people with asthma or cystic fibrosis can develop allergic disease, those with damaged lungs can develop chronic forms, and severely immunocompromised people can develop invasive infection.
At a glance
Quick facts
- Organism
- Aspergillus mold
- Exposure
- Environmental spores
- Person-to-person
- Not typical
- Main forms
- Allergic · chronic · aspergilloma · invasive
- Main organ
- Lungs / airways
- Severe form
- Invasive aspergillosis
Names & terminology
How this entity may be named or searched
- Aspergillosis
- Umbrella term covering allergic, colonizing/chronic and invasive diseases caused by Aspergillus.
- ABPA
- Allergic bronchopulmonary aspergillosis, an immune hypersensitivity reaction usually seen with asthma or cystic fibrosis.
- Aspergilloma
- A fungal ball growing in a pre-existing lung cavity.
- Invasive aspergillosis
- Tissue-invasive infection, usually in people with major immune compromise; it can spread beyond the lungs.
Structured entity profile
Clinical profile
Overview
Aspergillus is widespread in soil, dust, decaying vegetation and indoor or outdoor air. Inhaling spores is routine and does not usually cause illness. Disease develops when a susceptible airway, damaged lung structure or weakened immune system changes how the body handles the fungus. Aspergillosis is not generally acquired from another person. [1] [2]
The major clinical syndromes are distinct. Allergic bronchopulmonary aspergillosis (ABPA) is an allergic airway reaction; aspergilloma is a fungal ball within a pre-existing cavity; chronic pulmonary aspergillosis causes progressive lung disease over months or years; and invasive aspergillosis enters lung tissue and sometimes the bloodstream, especially after transplantation, prolonged neutropenia or other major immunosuppression. [1] [2] [3]
Symptoms and warning signs
Cough and shortness of breath are common across several forms. ABPA can cause wheeze and worsening asthma symptoms. Chronic pulmonary disease can cause weight loss, fatigue, persistent cough and coughing up blood. Aspergilloma may be asymptomatic or cause recurrent hemoptysis. Invasive disease often causes fever that does not respond to antibacterial therapy, chest pain, cough, breathlessness or hemoptysis, with additional symptoms if infection spreads to other organs. [1] [2]
SYMPTOM MATRIX
Symptoms are shaped by the type of aspergillosis and the host
Immune status and underlying lung disease are as important as the fungal species itself.
- Cough
- Shortness of breath
- Wheeze in allergic disease
- Fatigue
- Chest discomfort
- Coughing up blood
- Weight loss in chronic disease
- Fever in invasive disease
- Poorly controlled asthma or cystic fibrosis
- Known old lung cavity / prior tuberculosis
- Immunocompromised person with persistent fever
- Coughing significant amounts of blood
- New severe breathlessness or chest pain
- Neurologic symptoms in suspected disseminated infection
Invasive aspergillosis can progress quickly and requires urgent specialist assessment.
Diagnosis
Diagnosis begins with identifying the syndrome and risk group. Chest CT can show cavities, nodules, infiltrates or other patterns that direct testing, but imaging alone is not specific. Respiratory culture or microscopy can detect Aspergillus, yet a positive culture may represent colonization rather than invasive disease. [2] [3]
Tests are selected to match the syndrome: Aspergillus-specific IgE and total IgE support ABPA assessment; Aspergillus IgG is important in chronic pulmonary aspergillosis; galactomannan or other fungal biomarkers may support invasive-disease diagnosis in selected high-risk patients; bronchoscopy and tissue biopsy can provide stronger evidence when feasible. [2] [3]
Diagnostic pathway
Classify the syndrome before interpreting a fungal test
The same positive Aspergillus result can mean allergy, colonization, chronic disease or invasive infection depending on context.
A positive respiratory culture does not, by itself, prove invasive aspergillosis.
Who is at risk for each form?
ABPA occurs mainly in people with asthma or cystic fibrosis. Aspergilloma and chronic pulmonary aspergillosis usually require pre-existing structural lung damage such as cavities from prior tuberculosis, sarcoidosis, emphysema or other chronic disease. Invasive aspergillosis is concentrated among people with profound or prolonged immune suppression, including some stem-cell or organ transplant recipients, people with prolonged neutropenia and those receiving certain high-intensity immunosuppressive therapies. [1] [2]
Major clinical forms
ABPA: allergic inflammation can worsen asthma and cause bronchiectasis if uncontrolled. Aspergilloma: a fungal ball may remain stable or cause significant bleeding. Chronic pulmonary aspergillosis: cavities and fibrosis can progress over months or years. Invasive aspergillosis: fungal hyphae invade tissue and blood vessels and may disseminate, making rapid treatment critical. [2] [3]
Treatment and management
Treatment depends on the subtype. ABPA often requires control of airway inflammation, commonly with corticosteroid-based therapy, with antifungal therapy used in selected patients. An asymptomatic stable aspergilloma may be observed, while significant hemoptysis can require embolization or surgery. Chronic pulmonary aspergillosis usually requires prolonged oral antifungal therapy and specialist follow-up. [2] [3]
Invasive aspergillosis requires urgent systemic antifungal therapy; triazole-based treatment is commonly first-line, with regimen selection influenced by prior prophylaxis, drug interactions, organ function and local resistance. Reducing immunosuppression when feasible and managing neutropenia or other host factors can be as important as the antifungal drug. [2] [3]
Treatment & care hub
Treat the aspergillosis syndrome, not the culture result
Allergic, chronic and invasive disease require different therapeutic strategies.
Control airway inflammation
Anti-inflammatory treatment is central; antifungals may reduce fungal burden in selected patients.
Use prolonged antifungal therapy
Chronic pulmonary disease often needs months of therapy and imaging/serologic monitoring.
Observe or control bleeding
Stable disease may be observed; significant hemoptysis can need embolization or surgery.
Start systemic antifungal treatment promptly
High-risk patients require urgent specialist therapy and management of immune risk factors.
Azole antifungals have important drug interactions and require specialist prescribing and monitoring.
Exposure and prevention in high-risk patients
Because Aspergillus spores are common in the environment, complete avoidance is impossible. People with severe immune suppression may receive antifungal prophylaxis and environmental precautions according to transplant, hematology or infectious-disease protocols. Routine masks or household cleaning measures are not substitutes for medical prophylaxis in very high-risk patients. [1] [3]
Follow-up and treatment response
Response is judged using symptoms, imaging and the tests relevant to the subtype. Chronic and invasive aspergillosis often require repeated CT imaging and attention to antifungal toxicity, drug levels or interactions. ABPA follow-up also tracks asthma control and immunologic markers. Relapse can occur, particularly when underlying lung or immune risk persists. [2] [3]
Exposure vs disease
Exposure is common; clinically important aspergillosis is concentrated in susceptible hosts
Most people inhale Aspergillus spores without becoming ill.
Common questions
Frequently asked questions
Aspergillosis is generally acquired by inhaling environmental spores and is not usually spread person to person.
ABPA is an allergic airway reaction, whereas invasive aspergillosis involves fungal invasion of tissue, usually in a severely immunocompromised person.
No. Aspergillus can colonize damaged airways; diagnosis requires the clinical syndrome, imaging and appropriate mycologic or tissue evidence.
Yes. Hemoptysis can occur with aspergilloma, chronic pulmonary disease and invasive infection and may be severe.
Treatment ranges from anti-inflammatory therapy for allergic disease to prolonged or urgent antifungal therapy for chronic or invasive disease; some aspergillomas need procedural or surgical care.
Sources
- CDC — Aspergillosis Basics
- CDC — Symptoms of Aspergillosis
- IDSA — Clinical Practice Guideline for the Diagnosis and Management of Aspergillosis
- CDC — Risk Factors for Aspergillosis
This article is based on trusted medical sources and is awaiting clinician review. It is not a substitute for personalized medical advice.